You don't need to be a biologist to know about the dangerous bugs out there.
One pathogen or another, the news media direly report, is working its way around the world, from Central Africa, to Thailand, to China and to the slums of every major city in Europe.
Whether it's Ebola fever, SARS, bird flu, West Nile virus or HIV-AIDS, deadly infection seems to be only a casual contact or an incoming international flight away.
But while these microscopic threats to world health are the "stars" for epidemiologists and doomsayers alike, a prevalent, less exotic organism that's more likely to carry us off is still playing cat-and-mouse with researchers.
It's an ancient parasitic fungus called Pneumocystis carinii, and it's as common as the often deadly pneumonia it causes in the sick, the aged, infants and, above all, people whose immune defense system is suppressed by chronic illness like AIDS--or by the medications with which they are being treated.
Pneumocystis left the closeted world of bioscience and appeared increasingly in everyday language when the AIDS epidemic exploded in the 1980s. As the No. 1 AIDS-associated infection, it became a major diagnostic feature of the disease.
So, if it's been around so long, why hasn't medical science been able to take it out?
The reason is that for nearly a century since researchers first realized pneumocystis existed, and the widespread threat it posed, it has dodged identification and definition, let alone any really effective attempts to target it with drugs.
But now, thanks to work under way by UC scientists and other researchers involved in the international Pneumocystis Genome Project, the game might finally be up for this elusive killer.
The difficulty in nailing pneumocystis, explains UC research microbiologist Melanie Cushion, PhD, project leader of the Genome Project, has been in finding a way to culture it, or grow it, outside the human lung. Only then can researchers see what they're really dealing with and determine how to control it.
Dr. Cushion, a professor in UC's infectious diseases division and a world-renowned authority on pneumocystis, works at the Cincinnati VA Medical Center and recently received the VA's Research Career Scientist (RCS) Award, which pays her salary, to continue the study of pneumocystis for five more years. She is only the third Cincinnati scientist to receive the RCS, the highest award for nonclinician VA scientists, in the last 20 years.
Behaving like the true host-dependent parasite it is, says Dr. Cushion, pneumocystis has long existed unseen, unsuspected and for the most part harmlessly in human lungs, and also as a "species specific" guest in certain other mammals.
"Pneumocystis doesn't want to kill us," says Dr. Cushion, "unlike a nasty organism like Ebola, which jumps species--something that pneumocystis doesn't do--and hasn't been able to establish this balance with its host."
In contrast to some of the current big name bugs, pneumocystis is a relatively well-behaved live-in. That is until its host is weakened--by sickness, age, chemotherapy, radiation therapy or some other treatment that suppresses the body's defensive immune system.
And then it too becomes a killer.
Although pneumocystis was first identified in 1912, no one was able to culture it, or "grow it out," to provide material for study, and it sank into obscurity.
"It's a mysterious organism," Dr. Cushion says. "We don't know how it's transmitted, although we think it's through the air. With most fungi you can find a spore ... but with pneumocystis we don't even know what the agent of transmission looks like. Nor do we understand what it is that causes the infection, and how it gets out of the host, either.
"It's able to camouflage itself É it's very clever that way," she says. "That's probably how it's been able to live in a normal host without causing infection, and to avoid immune surveillance and destruction."
In the 1960s and 1970s, when cancer chemotherapy became widely available, pneumocystis attracted attention again.
"By then we could study it using electronmicroscopy, and that's when we really got a handle on it and what it looked like," Dr. Cushion says.
Then, in the 1980s, the worldwide AIDS epidemic began.
"And boom, there it was again!" says Dr. Cushion.
Pneumocystis was back, big time, she says. But this time, thanks to genetic analysis, "we were able to rip off the camouflage."
"Since we didn't have a culture system to grow it and study its metabolism," she says, "we had to see what genes it has, what it can do."
"Before we started this project, only about 20 pneumocystis genes were known. We estimate now it's got about 4,000," says Dr. Cushion.
"That's a pretty small genome, actually, but we're finding that unlike in the human genome, there's not a lot of extraneous 'junk DNA.'
"Pneumocystis isn't like many other parasitic genomes that have lost a lot of stuff because they're in a very intimate relationship with their host. It's retained much of its biosynthetic ability. So that's promising. We can start to target some of these things."
Problems remain, however. After overcoming the shortage of purified study material, the researchers had difficulty cloning some of the pneumocystis genome regions, due to the complex way they encode their "building block" amino acids.
In addition, pneumocystis has a lot of repetitive DNA "gene families," especially at the end of the chromosome. These repetitive genes, which encode the surface of the organism, are the antigens that alert the body's defense system that it has a target. With at least 100 encoding genes on its surface, pneumocystis seems able to baffle the immune system by reorganizing genetic variations of these genes.
But there is good news--"One of the breakthroughs we have right now is the PCR, or polymerase chain reaction, which can amplify segments of the genome, so long as we know what the sequence is. If you have a DNA sequence to a gene, the polymerase enzyme will make copies, and keep making copies so it becomes detectable."
While pneumocystis is troublesome enough for patients with depressed immune systems, it now appears to be spreading into different subpopulations. It's been recognized in underlying chronic diseases like chronic obstructive pulmonary disorder (COPD) and cancer, especially lung carcinoma, and there's now evidence from Chile that it might also be involved in sudden infant death syndrome (SIDS).
One of her team's major goals, says Dr. Cushion, is to use genetic analysis to find drug targets in pneumocystis, so new medications can be developed to treat it.
Although a commonly used antibiotic, Bactrim, works well against pneumocystis associated with AIDS, half the patients can't tolerate it, and evidence is emerging that the organism is mutating genetically in a way that helps it resist the standard treatment.
"We're finding these drug-resistant mutations in pneumocystis and other organisms, like malaria, all over the globe," Dr. Cushion says. "They've already spread through the human population within a decade.
"People thought we were crazy when we began the Pneumocystis Genome Project," Dr. Cushion observes, "because all the other organisms that have been sequenced have a nice culture system that allows you to grow buckets of them, then isolate the DNA and RNA so you have as much as you need to work with.